Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics announced a research collaboration with The University of Texas MD Anderson Cancer Center to analyze the use of Merck’s (known as MSD outside the US and Canada) Keytruda (pembrolizumab), a type of immunotherapy drug used in cancer treatment, in multiple cancer types. The project will use Lunit’s proprietary AI solution for tissue data analysis, Lunit SCOPE IO.
AIThority News: Core BTS Announces New AI Consulting Services to Help Clients Accelerate use of GenAI Technologies
Lunit will collaborate with Aung Naing, M.D., professor of Investigational Cancer Therapeutics at MD Anderson, as the lead Principal Investigator (PI) for this study. The goal of the study is to evaluate AI technology with the objective of improving patient data analysis and increasing the effective use of treatment for patients with different types of cancer. Lunit and Dr. Naing team plans to assess Merck’s clinical data by leveraging the capabilities of Lunit SCOPE IO, AI software that analyzes H&E-stained tissue slides to enable immune phenotyping and more.
There is currently a lack of effective biomarkers for immunotherapy,” said Brandon Suh, CEO of Lunit. “Existing methods have limitations. The landscape is changing rapidly and state-of-art technologies such as AI are playing a significant role in enabling new biomarkers. We are particularly excited to be working with Dr. Naing to analyze biomarkers for pembrolizumab, one of the most important immunotherapy drugs.”
Lunit SCOPE IO has been trained with more than 500,000 H&E slides and more than 10 million cell annotations from over 150 pathologists. It detects cancer area, stroma, and tumor infiltrating lymphocytes (TIL), an important immune cell type that plays a key role in immunotherapy. Among other analyses, SCOPE IO generates an immune phenotype map based on TIL density within the tumor microenvironment, and supports analysis in more than 16 cancer types.
Lunit is a deep learning-based medical AI company on a mission to conquer cancer. Our focus is on developing AI solutions for precision diagnostics and therapeutics, ensuring the right diagnosis, and treatment, at the right cost for each patient. Lunit is devoted to developing advanced medical image analytics and AI-based biomarkers via cutting-edge technology.
Recommended: AiThority Interview with Natalie Schwartz, Head of Global Brand Marketing and Partnerships at Canva
Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. As a medical AI company grounded on clinical evidence, the company’s findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences, including ASCO and AACR.
AIThority News: New Slack Innovations and Salesforce Customer 360 Integrations Unlock Team Productivity, Adding Value to the Digital HQ
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.